CRISM Therapeutics Corporation
AMMCF
$6.77
$6.573,309.57%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 18.80K | 18.80K | 18.80K | 18.80K | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 18.80K | 18.80K | 18.80K | 18.80K | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 0.00 | 1.24M | 2.48M | 2.35M | 2.22M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.00 | 1.24M | 2.48M | 2.35M | 2.22M |
| Operating Income | 0.00 | -1.24M | -2.48M | -2.35M | -2.22M |
| Income Before Tax | 0.00 | -1.43M | -2.86M | -2.73M | -2.61M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 0.00 | -1.43 | -2.86 | -2.73 | -2.61 |
| Earnings from Discontinued Operations | -9.65M | -8.54M | -7.43M | -3.92M | -408.00K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.65M | -9.97M | -10.29M | -6.65M | -3.01M |
| EBIT | 0.00 | -1.24M | -2.48M | -2.35M | -2.22M |
| EBITDA | -67.40K | -253.10K | -438.90K | -1.23M | -1.95M |
| EPS Basic | -1.11 | -1.15 | -1.18 | -0.76 | -0.35 |
| Normalized Basic EPS | 0.00 | -0.09 | -0.18 | -0.17 | -0.16 |
| EPS Diluted | -1.11 | -1.15 | -1.18 | -0.76 | -0.35 |
| Normalized Diluted EPS | 0.00 | -0.09 | -0.18 | -0.17 | -0.16 |
| Average Basic Shares Outstanding | 34.82M | 34.81M | 34.81M | 34.80M | 34.79M |
| Average Diluted Shares Outstanding | 34.82M | 34.81M | 34.81M | 34.80M | 34.79M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -325.98% | -304.71% | -284.76% | -220.25% | -- |
